prof. dr. H.M. (Helena) Verkooijen

Full Professor

  • Department of Epidemiology
  • Clinical Trial Office
  • Julius Center Research Program Cancer

prof. dr. H.M. (Helena) Verkooijen


Professor of Evaluation of Image-Guided Treatment, dedicated to improve the life of people with cancer. Committed to full integration of clinical research in routine patient care in order to facilitate undelayed evidence-based implementation of innovations in oncology.

Leader (PI) of several international (H2020) research consortia and academic industrial partnership, head of clinical research office and investigator in a range of (international) scientific studies. Strong background in teaching and development of educational modules at graduate and postgraduate level. Large international academic experience in Europe and Asia. Experienced speaker, moderator, and panel member.

Within the Division of Imaging and Cancer of the UMC Utrecht, I am responsible for clinical evaluation of innovative cancer treatments, and for evaluating to what extent theoretical benefits of these innovations translate into real benefits for patients. I lead a team of post-doc researchers, PhD students, and (medical) graduate students. I also lead the division’s clinical research office, which is responsible for trial support, data management, IT solutions, quality control and medico-ethical advise (supporting 200 academic researchers).

I lead two international consortia (one H2020 European, one transatlantic) and collaborate closely with (international) academic and industry partners. I am regularly invited as speaker at international conferences, educational sessions and consortium meetings, and as panelist at meetings/debates of professional organizations. I serve as a member in several scientific advisory boards and expert committees.

I am Strategic Advisor for 'NTvG Gezonde Zorg', a campaign of the Dutch Journal of Medicine (Nederlands Tijdschrift voor Geneeskunde). This campaign contributes to ensuring sustainability and affordability of health care in the Netherlands by exposing the harms of medicalisation (overdiagnosis and overtreatment) and explicitly demonstrating the power of (primary) prevention. 

Side Activities

    • Strategic Advisor 'NTvG Gezonde Zorg'
    • Board Member Dutch Breast Cancer Research Group (Borstkanker Onderzoek Groep, BOOG)
    • Member Scientific Advisory Board Dutch Expert Centre for Screening
    • Board Member J.M. Fentener van Vlissingen Fonds
    • Member Scientific Advisory Board Dutch Prospective Colorectal Cancer Cohort (PLCRC)
    • Member Expert Committee Value-Based Health Care Breast Cancer (NFU)

Research Output (266)

The effect of chemotherapy on subjective cognitive function in younger early-stage breast cancer survivors treated with chemotherapy compared to older patients

Gregorowitsch M L, Ghedri A, Young-Afat D A, Bijlsma R, Baas I O, van Schaik-van de Mheen C, Agterof M J, Göker E, Ten Bokkel Huinink D, van den Bongard H J G D, Verkooijen H M, jun 2019, In: Breast Cancer Research and Treatment. 175 , p. 429-441 13 p.

Behandeling voor kanker:er valt iets te kiezen

Boersma Liesbeth J., Sonke Gabe S., Verkooijen Helena M. 31 mei 2019, In: Nederlands Tijdschrift voor Geneeskunde. 163

Systematic review of the role of stereotactic radiotherapy for bone metastases

Spencer Katie, van der Velden Joanne M, Wong Erin, Seravalli Enrica, Sahgal Arjun, Chow Edward, Verlaan Jorrit-Jan, Verkooijen Helena M, van der Linden Yvette M 23 mei 2019, In: Journal of the National Cancer Institute. 111 , p. 1023-1032 10 p.

Physical activity levels of women with breast cancer during and after treatment, a comparison with the Dutch female population

Gal R., Monninkhof E. M., Peeters P. H.M., van Gils C. H., van den Bongard D. H.J.G., Wendel-Vos G. C.W., Zuithoff N. P.A., Verkooijen H. M., May A. M. 4 mei 2019, In: Acta Oncologica. 58 , p. 673-681 9 p.

Trends in the risk of cardiovascular disease in women with breast cancer in a Dutch nationwide cohort study

Buddeke Josefien, Gernaat Sofie A. M., Bots Michiel L., van den Bongard Desiree H. J. G., Grobbee Diederick E., Vaartjes Ilonca, Verkooijen Helena M. mei 2019, In: BMJ Open. 9 , p. e022664

The effect of time interval from chemoradiation to surgery on postoperative complications in patients with rectal cancer

Couwenberg Alice M, Intven Martijn P W, Hoendervangers Sieske, van der Sluis Frederik J, van Westreenen Henderik L, Marijnen Corrie A M, van Grevenstein Wilhelmina M U, Verkooijen Helena M, 25 apr 2019, In: European Journal of Surgical Oncology. 45 , p. 1584-1591 8 p.

Delayed presentation to a spine surgeon is the strongest predictor of poor postoperative outcome in patients surgically treated for symptomatic spinal metastases

van Tol Floris R, Choi David, Verkooijen Helena M, Oner F Cumhur, Verlaan Jorrit-Jan 18 apr 2019, In: The Spine Journal. 19 , p. 1540-1547

Effect of short-course radiotherapy on postoperative complications in locally advanced rectal cancer

Hoendervangers S., Sparreboom C., Van Grevenstein H., Verkooijen L., Lange J., Doornebosch P., Intven M. apr 2019, In: Radiotherapy and Oncology. 133 , p. S429-S429

Recalcification in lytic bone metastases of the spine after radiotherapy

Pielkenrood B., Visser T., Foppen W., Van der Velden J., Eppinga W., Kasperts N., Bol G., Verkooijen L., Verlaan J. apr 2019, In: Radiotherapy and Oncology. 133 , p. S878-S878

Cosmetic outcome in irradiated breast cancer patients and association with patient reported outcomes

Batenburg M., Gregorowitsch M., Van den Bongard D., Maarse W., Verkooijen H. apr 2019, In: Radiotherapy and Oncology. 133 , p. S128-S128

All Research Output (266)